Screener
Baxter International BAX Pharmaceuticals — Depreciation
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Baxter International’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028962
FAQ
- What is Baxter International's pharmaceuticals — depreciation?
- Baxter International (BAX) reported pharmaceuticals — depreciation of $16M in Q1 2026.
- How has Baxter International's pharmaceuticals — depreciation changed year-over-year?
- Baxter International's pharmaceuticals — depreciation decreased by 0.0% year-over-year, from $16M to $16M.
- What is the long-term trend for Baxter International's pharmaceuticals — depreciation?
- Over 4 years (2021 to 2025), Baxter International's pharmaceuticals — depreciation has grown at a -2.2% compound annual growth rate (CAGR), from $71M to $65M.
- What does pharmaceuticals — depreciation mean?
- Represents the systematic allocation of the cost of tangible assets, such as manufacturing equipment and facilities, over their useful lives within the Pharmaceuticals segment. It is a non-cash expense that reflects the wear and tear of capital assets.
Ask your AI about Baxter International's pharmaceuticals — depreciation.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude